PapersFlow Research Brief
Cystic Fibrosis Research Advances
Research Guide
What is Cystic Fibrosis Research Advances?
Cystic Fibrosis Research Advances encompass studies on the genetic basis, molecular mechanisms, therapeutic interventions, pulmonary infections, and management strategies for cystic fibrosis, a genetic disorder affecting epithelial cells primarily in the lungs and pancreas.
The field includes 80,964 works focused on topics such as CFTR gene mutations, microbiota analysis, bronchiectasis, and nutrition management. Key discoveries involve cloning and characterizing the cystic fibrosis gene on chromosome 7, as detailed in foundational papers from 1989. Research also addresses therapeutic opportunities like kinase inhibitors and updates on emerging clinical challenges.
Topic Hierarchy
Research Sub-Topics
CFTR Modulator Therapies
CFTR modulators including potentiators (ivacaftor) and correctors (lumacaftor, tezacaftor) restore channel function in specific mutations. Clinical trials evaluate combination therapies like triple combinations for broad genotype coverage.
Cystic Fibrosis Pulmonary Exacerbations
Research defines exacerbation phenotypes, biomarkers for early detection, and randomized trials of treatment duration and antibiotic strategies. Studies address lung function decline trajectories and hospitalization predictors.
Cystic Fibrosis Airway Microbiota
Metagenomic studies characterize chronic infections beyond Pseudomonas including anaerobes, Staphylococcus, and viral communities. Research examines succession patterns, antibiotic resistance, and microbiome-targeted therapies.
CFTR Genotype-Phenotype Correlations
Large cohort studies correlate CFTR mutations with clinical outcomes including pancreatic sufficiency, meconium ileus, and modifier gene effects. Functional assays classify mutations for personalized therapy selection.
Cystic Fibrosis Nutritional Management
Nutritional research addresses pancreatic insufficiency, CFRD, and growth faltering using enzyme replacement, oral supplements, and enteral feeding protocols. Longitudinal studies link BMI trajectories to pulmonary outcomes.
Why It Matters
Cystic fibrosis research has identified the CFTR gene, enabling mutation-specific diagnostics and therapies that address the root cause of ion transport defects in affected tissues. Riordan et al. (1989) cloned complementary DNA for the cystic fibrosis gene, achieving 7376 citations and facilitating targeted genetic analysis. Kerem et al. (1989) pinpointed the ΔF508 mutation in 70 percent of patients, supporting precision medicine approaches. Jennings et al. (2014) highlighted survival increases to affect approximately 70,000 individuals worldwide through new therapies for sinopulmonary disease and pancreatic function loss. Meijer et al. (2016) proposed (R)-roscovitine for modulating immunity, advancing treatments for pulmonary infections with 4996 citations.
Reading Guide
Where to Start
Start with 'Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA' by Riordan et al. (1989), as it provides the foundational discovery of the CFTR gene with direct evidence from cDNA cloning and transcript detection in affected tissues.
Key Papers Explained
Riordan et al. (1989) cloned the CFTR cDNA in 'Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA', building the basis for Rommens et al. (1989) to map the locus via chromosome walking in 'Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping'. Kerem et al. (1989) then identified the ΔF508 mutation in 'Identification of the Cystic Fibrosis Gene: Genetic Analysis', linking genetics to 70 percent of cases. Meijer et al. (2016) extended this to immunity modulation with (R)-roscovitine in 'Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis'. Jennings et al. (2014) reviewed clinical challenges in 'Update on Key Emerging Challenges in Cystic Fibrosis'.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research builds on CFTR genetics toward mutation-specific therapies and infection control, as seen in spirometry standardization by Graham et al. (2019) and microbiota probes by Amann et al. (1990). No recent preprints or news available indicate focus remains on established interventions like kinase inhibitors.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Identification of the Cystic Fibrosis Gene: Cloning and Charac... | 1989 | Science | 7.4K | ✕ |
| 2 | Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Po... | 2016 | Journal of Innate Immu... | 5.0K | ✓ |
| 3 | Cystic Fibrosis | 2006 | — | 4.4K | ✕ |
| 4 | Identification of the Cystic Fibrosis Gene: Genetic Analysis | 1989 | Science | 4.1K | ✕ |
| 5 | Combination of 16S rRNA-targeted oligonucleotide probes with f... | 1990 | Applied and Environmen... | 4.0K | ✓ |
| 6 | Standardization of Spirometry 2019 Update. An Official America... | 2019 | American Journal of Re... | 3.7K | ✓ |
| 7 | Update on Key Emerging Challenges in Cystic Fibrosis | 2014 | Medical Principles and... | 3.7K | ✓ |
| 8 | A Comparison of Bayesian Methods for Haplotype Reconstruction ... | 2003 | The American Journal o... | 3.5K | ✓ |
| 9 | Identification of the Cystic Fibrosis Gene: Chromosome Walking... | 1989 | Science | 3.2K | ✕ |
| 10 | Clinical Practice Guidelines for the Management Candidiasis: 2... | 2009 | Clinical Infectious Di... | 3.2K | ✓ |
Frequently Asked Questions
What is the primary genetic defect identified in cystic fibrosis?
Approximately 70 percent of cystic fibrosis mutations result in a three-base-pair deletion causing loss of phenylalanine at position 508 in the CFTR protein. Kerem et al. (1989) confirmed this ΔF508 mutation through genetic analysis in 'Identification of the Cystic Fibrosis Gene: Genetic Analysis'. This finding guides mutation screening and therapy development.
How was the cystic fibrosis gene located and cloned?
Riordan et al. (1989) isolated overlapping cDNA clones from epithelial cell libraries using a genomic segment on chromosome 7 in 'Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA'. Rommens et al. (1989) used chromosome walking and jumping to map the locus in 'Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping'. These methods detected 6500-nucleotide transcripts in affected tissues.
What therapeutic potential does (R)-roscovitine offer for cystic fibrosis?
Meijer et al. (2016) showed (R)-roscovitine, a kinase inhibitor in phase II trials for other diseases, modulates innate and adaptive immunity in 'Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis'. It targets pulmonary infections and inflammation. The compound supports investigation as a cystic fibrosis agent.
What are key emerging challenges in cystic fibrosis management?
Jennings et al. (2014) outlined challenges including chronic sinopulmonary disease and pancreatic exocrine loss in approximately 70,000 patients worldwide in 'Update on Key Emerging Challenges in Cystic Fibrosis'. New therapies have increased survival. Management strategies address bronchiectasis and infections.
How is spirometry standardized for cystic fibrosis lung assessment?
Graham et al. (2019) updated spirometry standards for diagnosing lung diseases like cystic fibrosis in 'Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement'. It provides objective lung function data. The guidelines replace 2005 versions for consistent monitoring.
What methods analyze cystic fibrosis microbiota?
Amann et al. (1990) developed 16S rRNA-targeted probes with flow cytometry for mixed microbial populations in cystic fibrosis lungs in 'Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations'. Probes label cells for phylogenetic analysis. This aids pulmonary infection studies.
Open Research Questions
- ? How can CFTR modulators address rare mutations beyond ΔF508?
- ? What immune pathways does (R)-roscovitine target to reduce cystic fibrosis pulmonary exacerbations?
- ? How do microbiota dynamics influence bronchiectasis progression in cystic fibrosis?
- ? Which novel therapies extend survival beyond current levels for the 70,000 affected individuals?
- ? How do genetic haplotypes predict cystic fibrosis disease severity?
Recent Trends
The field comprises 80,964 works with sustained impact from 1989 gene discovery papers: Riordan et al. (7376 citations), Kerem et al. (4103 citations), and Rommens et al. (3226 citations).
Later advances include Meijer et al. (2016, 4996 citations) on roscovitine and Jennings et al. (2014, 3659 citations) on challenges affecting 70,000 patients.
Spirometry updates by Graham et al. (2019, 3667 citations) support lung monitoring amid stable growth.
Research Cystic Fibrosis Research Advances with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cystic Fibrosis Research Advances with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers